| Summary: | Ozenoxacin 1% cream is a topical non-fluorinated quinolone antibiotic indicated for the treatment of impetigo in patients aged two months or older. The recommended use for ozenoxacin is the application of a thin layer of cream to affected areas twice daily for five days. It is available in 10 g tubes at $17.78 per tube, or $1.78 per gram. The manufacturer submitted a cost-utility analysis with a 14-day time horizon -- conducted from a Canadian public health care payer perspective -- which compared ozenoxacin to fusidic acid and mupirocin (the two topical antibiotics available in Canada). The submitted model was in the form of a decision tree with patients receiving a topical antibiotic treatment and subsequently experiencing cure or no cure based on treatment efficacy. An indirect treatment comparison was used to compare the treatment efficacy of ozenoxacin to fusidic acid, while a Cochrane systematic review and CADTH Rapid Response were used to support the assumption of equal efficacy between fusidic acid and mupirocin. The manufacturer reported that ozenoxacin is less costly and is associated with greater quality-adjusted life-years (QALYs) (dominant) compared with fusidic acid, and the incremental cost-utility ratio (ICUR) compared with mupirocin was $55,792 per QALY.
|
|---|